COMTECH TELECOMMUNICATIONS CORP /DE/ (CMTL) stock intrinsic value fair value estimate & owner earnings analysis

Comtech Telecommunications has two businesses. Satellite and Space Communications (fiscal 2025 sales of $269.3 million) makes satellite ground equipment, troposcatter radios and space electronics for the U.S. Army, Marine Corps and international customers. Allerium (sales of $230.3 million, up 6.5%) provides next-generation 911 call-handling and location services to state and local 911 authorities and to top-tier U.S. wireless carriers. Total sales were $499.5 million, down from $540.4 million. What changed since our last review. Our August 2026 review showed $0.00, $1.72 and $9.41 for the bear, base and bull cases. This update is much lower, for two reasons that are corrections rather than a change in mood. First, the earlier work counted only about $74 million of net debt, while the obligations ahead of common shareholders are about $440 million once the subordinated loan and the convertible preferred stock are included. Second, the earlier work overstated stock compensation, which is $3 million to $15 million a year, not $26 million to $79 million. Offsetting good news is credited: the nine-month loss to April 30, 2026 shrank to $33.0 million from $163.2 million, operating cash flow turned positive at $19.1 million, and on June 15, 2026 the company signed a $157.5 million cash sale of most of Satellite and Space to Gilat. What stands ahead of the shares. Shareholders sit behind three groups of claims, all held largely by the same investors. (1) A senior term loan and revolver of about $117 million after repayments this fiscal year, priced at roughly SOFR plus 10.5% and due no later than July 31, 2028. (2) A subordinated loan of about $107 million including interest added to principal, due 90 days after the senior loan; $65 million of it carries make-whole payments of 33% to 75% of principal if repaid early. (3) Convertible preferred stock with a claim of about $218 million (its stated claim was $208.7 million on October 31, 2025 and grows at 9% a year); it converts only at $7.99 a share, and holders can require repurchase on a qualifying asset sale, from April 30, 2027 under certain conditions, or from October 31, 2028. That is about $442 million against $28.5 million of cash, of which we treat $13.5 million as spare after the $15 million minimum liquidity the loans require. Because these claims cost 9% to about 15% a year against our 6% yardstick, and the make-whole feature and warrants are carried at $17.8 million, we add $66.6 million, so the business must cover about $495.1 million in every case. Covenant tests, suspended until then, resume with the period ending January 31, 2027 (maximum net leverage 3.30x, minimum fixed-charge coverage 1.04x, minimum EBITDA of $26 million rising to $32 million by October 2027). The going-concern doubt disclosed from December 2023 was removed in the fiscal 2025 annual report, but those covenant tests and the 2028 maturities are the main pressure points. Earnings power. We measure owner earnings as operating cash flow, less the swing in working capital, less stock compensation, less the capital spending needed just to stand still. On that basis, after interest, the business earned $2.13, $2.43 and $2.74 a share in fiscal 2017 to 2019 and $1.25 in 2020, then lost money every year: $(2.49) in 2021, $(0.97) in 2022, $(0.46) in 2023, $(0.46) in 2024 and $(0.98) in 2025. Before cash interest, which is the cash the business itself produces for its lenders, it produced about $(21.6) million in 2022, $(0.8) million in 2023, $4.9 million in 2024, $(1.0) million in 2025 and about $3.5 million in the first nine months of fiscal 2026 (roughly $4.7 million a year; cash interest was $13.9 million over the same nine months, and more interest was added to loan balances rather than paid). The earlier years describe a higher-margin business that lost its legacy contracts, so we measure from the restructuring under way since fiscal 2025, when gross margin rose from 12.5% in the first quarter to 31.2% in the fourth and 33.7% over the first nine months of fiscal 2026. Our starting level is $4.7 million a year, the median of fiscal 2024, fiscal 2025 and the fiscal 2026 nine-month pace. The last completed year's change was a decline (from $4.9 million to $(1.0) million), so year one assumes no growth: returning to a margin the business has already earned for three quarters is not counted as growth. Base case. The Gilat sale closes around year-end 2026 at $157.5 million, a signed agreement approved by both boards and subject to U.S. foreign-investment and antitrust clearance (worth $155.2 million today). The remaining business (Allerium plus the retained cyber and services work) keeps producing $4.7 million a year before interest, flat for ten years and fading to zero over the following ten as contracts run off, worth $44.0 million. The business is worth $199.2 million and owes about $495.1 million, a difference of about $(295.9) million, or $(9.92) a share on 29.8 million shares. In this case the company appears to owe roughly $296 million more than the business is worth. Bull case. Allerium keeps growing as it did in fiscal 2025, adding about $2.2 million a year to cash flow for five years (6.5% of its roughly $33.8 million of annual operating income plus depreciation and amortization, less capital spending), then holds flat for five years and fades over the next ten. The evidence: Allerium sales rose 6.5% and its segment operating income rose from $12.3 million in fiscal 2023 to $21.7 million and $24.1 million, backlog was $672.1 million at July 31, 2025, and a top-tier U.S. wireless carrier extended its contract in November 2025 for more than $130 million. With the sale at $155.2 million today and the remaining business worth $127.8 million, the business is worth $283.0 million against $495.1 million owed, a difference of $(212.0) million, or $(7.11) a share. Even here the shares appear to owe about $212 million more than the business is worth. Bear case. The Gilat sale is not completed (it needs U.S. foreign-investment and antitrust clearance, the buyer is an Israeli company, and the segment supplies U.S. military customers), and the company carries on at $2.0 million a year, the median of fiscal 2024 and 2025, flat for ten years and fading over the next ten, worth $18.7 million. Against $495.1 million owed the difference is $(476.4) million, or $(15.97) a share. With covenant tests returning in January 2027 and the loans maturing in 2028, lenders and preferred holders would likely control the outcome and shareholders would probably receive little or nothing. Each case's cash before interest ($2 million to $16 million a year) is far below the roughly $19 million a year of cash interest plus interest added to balances, which is why no case leaves value for shareholders; we did not assume lenders would tolerate that indefinitely. Growth credited and left out. Only the bull case credits growth, and only Allerium's, because a signed contract extension, a $672.1 million backlog and a demonstrated rise in segment profit support it. We left out any recovery in Satellite and Space, share gains, further margin expansion, a fall in corporate costs (unallocated corporate expenses were $46.8 million in fiscal 2025 and $32.9 million in 2023) and refinancing at lower rates, because none is contracted or already demonstrated. The sale price is fixed by contract, so it is credited in the base and bull cases. Accounting judgements. Amortization of acquired intangibles ($21.7 million in fiscal 2025), write-downs of receivables and inventory ($33.8 million) and the $79.6 million impairment do not use cash and are added back automatically; because the intangibles are wasting assets, we do not grow their earnings and we let them fade after ten years rather than lowering today's level. Working-capital cash inflows ($8.7 million in fiscal 2025 and $13.7 million in the nine months) are removed, since they are timing rather than earnings. We counted equity awards tied to the CEO transition in fiscal 2022 and 2023 as stock compensation, and treated all capital spending as maintenance in years when sales fell. Segment cash flows are not disclosed, so we assumed the businesses being sold add nothing to today's cash flow; that segment lost $32.1 million before impairment in fiscal 2025 (it earned $15.0 million in 2023 and $10.3 million in 2024), and if it in fact contributes cash, the remaining business is worth less than we show. Tests of the case. We checked two load-bearing points against the filings. The preferred stock does rank ahead of common shareholders with a $208.7 million claim, and at a $7.99 conversion price conversion would matter only if the shares were worth far more than any case here. And the size of the sale is fixed at $157.5 million, but at roughly 10 times the segment's adjusted earnings it does not come close to covering the claims ahead of the shares. What would make this wrong. If the sale closes, proceeds retire the costly senior and subordinated debt without heavy make-whole payments, and the remaining business earns four to five times the $4.7 million we use (for example if corporate costs fall sharply), the shares could be worth something. We could not reconcile about $2.0 million of fiscal 2022 cash flow from the statement lines, and the narrative of the most recent quarterly report was not available to us, so the fiscal 2026 figures rest on its reported numbers alone. Because all three cases are below zero, we see no price today at which the common shares offer a margin of safety; the picture should be revisited once the sale closes and the debt and preferred stock are addressed.